Vanzacaftor / tezacaftor / deutivacaftor · Alyftrek
Small molecule
Evidence outlook
Approved: Cystic Fibrosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (1)
- Cystic fibrosis in people aged 6 years and older with at least one non-Class I CFTR mutation
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05437120 NCT05437120 · Cystic Fibrosis Registry: NCT05437120 | 1 | Maximum Observed Plasma Concentration (Cmax) of VX-121, TEZ, D-IVA, and Relevant Metabolites (Cohort 1: Pre-dose up to Day 23; Cohort 2: Pre-dose up to Day 13); Area Under the Concentration Versus Time Curve (AUC) of VX-121,TEZ, D-IVA, and Relevant Metabolites (Cohort 1: Pre-dose up to Day 23; Cohort 2: Pre-Dose up to Day 13); Fraction Unbound (fu) for VX-121 and D-IVA in Plasma (Cohorts 1 and 2: Pre-dose up to Day 2); Unbound Maximum Observed Concentration (Cmax ub) for VX-121 and D-IVA (Cohorts 1 and 2: Pre-dose up to Day 2); Unbound Area Under the Concentration Versus Time Curve (AUC ub) of VX-121 and D-IVA (Cohorts 1 and 2: Pre-dose up to Day 2) 2023-03-16 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 2 more trials
NCT05033080 NCT05033080 · Cystic Fibrosis This was a randomized, quadruple-blind trial in 398 treated patients comparing the new combination against the active standard-of-care regimen. The primary endpoint, lung function (ppFEV1) at 24 weeks, met the pre-specified non-inferiority criterion (p<0.0001), with the new combination numerically matching or slightly exceeding the comparator (difference +0.2 percentage points, 95% CI -0.7 to 1.1). Registry: NCT05033080 | 3 | Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) (From Baseline Through Week 24) 2023-05-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
NCT05076149 NCT05076149 · Cystic Fibrosis This was a randomized, quadruple-blind trial in 573 treated patients comparing the new combination against the active standard-of-care regimen. The primary endpoint, lung function (ppFEV1) at 24 weeks, met the pre-specified non-inferiority criterion (p<0.0001), with the new combination numerically matching the comparator (difference +0.2 percentage points, 95% CI -0.5 to 0.9). Registry: NCT05076149 | 3 | Absolute Change in Percent Predicted Forced Expiratory Volume in 1second (ppFEV1) (From Baseline Through Week 24) 2023-05-18 | Completed. Key figures are not recorded here; the rationale explains the result. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek): this drug | Approved | Small molecule | CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| Elexacaftor / Tezacaftor / Ivacaftor (Trikafta) | Approved | Small molecule | CFTR, CFTR | Reliable signal | NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). | |
| Ivacaftor (Kalydeco) | Approved | Small molecule | CFTR | Partial signal | NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) | |
| Lumacaftor (Orkambi) | Approved | Small molecule | CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| Tezacaftor / Ivacaftor (Symdeko) | Approved | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| KB407 | Phase 1 | Gene therapy / editing | CFTR (gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| VX-828 | Phase 1 | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Luvomeran | Discontinued | RNA / oligonucleotide | CFTR (mRNA replacement) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Alyftrek (Vanzacaftor / tezacaftor / deutivacaftor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent